A high-performance liquid chromatography–tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma

An LC/MS/MS method was developed to quantify carboplatin and eribulin mesylate (E7389) in human plasma and urine. For carboplatin, sample clean-up by protein precipitation and supernatant injection into a Waters Spherisorb® S5 SCX column was used. Liquid-phase extraction and reverse-phase chromatography on a Polaris® C18 column were used for eribulin. Quantitation involved LC/MS/MS with positive electrospray ionization. Accuracy, precision, linearity, range, specificity, recovery and stability were also evaluated. Both compounds were stable in human plasma (≥80 days at −80 °C), at room temperature (≥4 h), following three freeze–thaw cycles and in 50/50 methanol/H2O (<4 °C for ≥252 days).